Buttram V, Izu A, Henzl M R
Am J Obstet Gynecol. 1979 Jul 1;134(5):575-8. doi: 10.1016/0002-9378(79)90844-5.
In a double-blind parallel trial, repeated doses of naproxen sodium (550 mg initially, followed by 275 mg every 6 hours as needed) and placebo were administered to a group of intrauterine contraceptive device (IUD) users in whom dysmenorrhea and premenstrual uterine pain developed or increased following the insertion of the IUD. Seventeen subjects were treated with naproxen sodium and 16 received placebo. The study covered three episodes of uterine pain and/or cramping. Efficacy of pain relief was judged by: (1) the overall relief which the patients experienced during the treatment and (2) the changes in the pain intensity (measured on a 6 point scale). By both these criteria, naproxen sodium was statistically significantly superior to placebo (p = 0.02); consequently, naproxen sodium appears to offer a new treatment modality for pain associated with IUD usage.
在一项双盲平行试验中，对一组宫内节育器（IUD）使用者给予重复剂量的萘普生钠（初始剂量550毫克，随后根据需要每6小时服用275毫克）和安慰剂。这些使用者在插入IUD后出现痛经和经前子宫疼痛或疼痛加剧。17名受试者接受萘普生钠治疗，16名接受安慰剂治疗。该研究涵盖了三个阶段的子宫疼痛和/或痉挛。通过以下方式判断止痛效果：（1）患者在治疗期间所体验到的总体缓解情况，以及（2）疼痛强度的变化（采用6分制测量）。根据这两个标准，萘普生钠在统计学上显著优于安慰剂（p = 0.02）；因此，萘普生钠似乎为与使用IUD相关的疼痛提供了一种新的治疗方式。
